Infliximab treatment in two Chinese patients with psoriatic arthritis |
| |
| Authors: | Xi Xie Jin-wei Chen Fen Li Jing Tian Jie-sheng Gao and David Zhang |
| |
| Institution: | (1) Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nurnberg, Erlangen, Germany |
| |
| Abstract: | Psoriatic arthritis (PsA) is a rheumatoid factor (RF)-seronegative systemic inflammatory disorder associated with psoriasis.
Current treatment for PsA in China is still focused on disease modifying anti-rheumatic drugs (DMARDs). In this paper, we
report two Chinese patients with active longstanding PsA treated with infliximab, a human-mouse chimeric monoclonal antibody
against tumor necrosis factor alpha (TNF-α). The results show that infliximab acted quickly and effectively in relieving peripheral
and axial symptoms and refractory skin lesions, even in recombinant human TNF-α receptor (rhTNFR)-resistant case. The take-home
message from our cases is that infliximab is a useful therapeutic option for refractory PsA, especially when a patient has
a combination of psoriasis and psoriatic arthritis. Further local evidence and experience must be accumulated in order to
make anti-TNF-α therapy more accessible to PsA patients in China. |
| |
| Keywords: | Refractory psoriatic arthritis Skin lesions Infliximab Anti-tumor necrosis factor alpha (TNF-α) treatment |
| 本文献已被 万方数据 SpringerLink 等数据库收录！ |
